MedTrace Logo

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

NCT00960479 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)

DRUG

Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

Sponsors & Collaborators

Principal Investigators

  • Piyush Patel, M.D. · Allied Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2001-02-28
Completion
2001-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960479 on ClinicalTrials.gov